biosimilars

Biosimilar drugs appear comparable to brand-name counterpartsSystematic review provides comprehensive first look at TNF-alpha biosimilar treatments.
New bill aims to support generic, biosimilar drug competitionThe CREATES Act came about because some pharmaceutical manufacturers are misusing the REMS program to prevent generic drug development.
Survey finds stakeholders lack understanding of biosimilarsIt is important to look at how the introduction of biosimilars in the United States may affect your business and your stakeholders and plan for those changes accordingly, according to a new report.
Biosimilars uptake may lag for cancer patients, physiciansBiosimilars will have a significant impact on cancer treatment, with the potential to drive cost savings, but will patients and providers be accepting?
Arizona passes pharmacy biosimilar lawArizona recently joined around 20 other states by passing a law allowing pharmacists to substitute certain interchangeable biosimilar drugs for brand name drugs.
The biosimilar balance: More options, lower costsThe fly in the ointment: CMS' current plan for HCPCS codes is a real buzz kill.
Predictions for the future of high-cost specialty drugsIMS Health expert predicts future drug spending trends and ways to curb rising costs at the AMCP 2016 conference.
Biosimilars pose problems for Medicare beneficiaries
Biosimilars pose problems for Medicare beneficiariesSurprisingly, Medicare beneficiaries are likely to pay much more for biosimilars than the referenced brand medication, according to a new report.
Three drug trends impacting specialty pharmacyAMCP session, “Specialty Pharmaceutical in Development,” highlighted critical trends that healthcare executives should be watching
Addressing rising pharma costs: A roundtable discussionAt the AMCP16 conference, Managed Healthcare Executive invited some of the nation’s leading pharmacy and managed care experts to join us to discuss some of the most critical managed care pharmacy challenges facing the industry.